Demographics and clinical characteristics of patients in Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (N=1440)
Women (n=541) | Men (n=899) | P value | |
Age, years, mean (SD) | 66.2±11.2 | 61.0±11.3 | <0.001 |
Clinical features | |||
Systolic BP, mm Hg (IQR) | 150(135-162) | 148(132-162) | 0.24 |
Diastolic BP, mm Hg (IQR) | 85 (78–91) | 89 (80–97) | <0.001 |
Glucose, mmol/L (IQR) | 6.8 (5.8–8.8) | 6.8 (5.8–8.4) | 0.06 |
Current smoking, n (%) | 25 (4.6) | 490 (54.4) | <0.001 |
Medical history | |||
Previous ischaemic stroke, n (%) | 96 (17.7) | 151 (16.8) | 0.64 |
Previous TIA, n (%) | 42 (9.3) | 84 (9.3) | 0.30 |
Hypertension, n (%) | 337 (62.3) | 507 (56.4) | 0.03 |
Hyperlipidaemia, n (%) | 35 (6.5) | 59 (6.6) | 0.94 |
Diabetes mellitus, n (%) | 116 (21.4) | 140 (15.6) | 0.005 |
Atrial fibrillation, n (%) | 137 (25.3) | 101 (11.2) | <0.001 |
Baseline medication | |||
Antiplatelets use before stroke, n (%) | 79 (14.6) | 112 (12.5) | 0.25 |
Anticoagulants use before stroke, n (%) | 9 (1.7) | 15 (1.7) | 0.99 |
Antihypertensive agents before stroke, n (%) | 236 (43.6) | 296 (32.9) | <0.001 |
Prestroke mRS 0–2, n (%) | 528 (97.8) | 884 (98.7) | 0.21 |
Median NIHSS on admission, mean (SD) | 12.3±6.8 | 11.6±6.7 | 0.04 |
Median stroke-to-visit time, min (IQR) | 1.2 (0.7–2.0) | 1.3 (0.8–2.2) | 0.04 |
Median stroke-to-imaging time, min (IQR) | 1.9 (1.3–2.9) | 1.8 (1.3–2.6) | 0.03 |
Median stroke-to-needle time, min | 0.04 | ||
0–3 hours, n (%) | 305 (56.5) | 449 (50.2) | |
3–4.5 hours, n (%) | 135 (25.0) | 239 (26.7) | |
>4.5 hours, n (%) | 100 (18.5) | 207 (23.1) | |
TOAST type | <0.001 | ||
LAA, n (%) | 272 (50.5) | 549 (61.7) | |
SAO, n (%) | 44 (8.2) | 83 (9.3) | |
CE, n (%) | 143 (26.6) | 116 (13.0) | |
Other, n (%) | 79 (14.7) | 142 (16.0) | |
Total length of stay (days) | 15 (11–21) | 14 (11–21) | 0.10 |
BP, blood pressure; CE, cardioembolism; LAA, large-artery atherosclerosis; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SAO, small-artery occlusion; TIA, transient ischaemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment.